Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

State-of-the-Science

This article was originally published in The Tan Sheet

Executive Summary

"Multivitamin/Mineral Supplements and Chronic Disease Prevention" is the topic of a State-of-the-Science Conference the Office of Dietary Supplements and the Office of Medical Applications of Research at NIH have scheduled for May 15-17 in Bethesda, Md. "What is the efficacy of MVM in chronic disease prevention in the general population of adults," is one of the questions slated for discussion. An "impartial, independent panel" will review currently available literature in advance of the conference including a "systemic literature review commissioned through the Agency for Healthcare Research and Quality." Presentations and open public discussions will be held May 15-16. On May 17, the "panel will present a statement of its collective assessment of the evidence." 1Registration ends May 12, 2006...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel